295 related articles for article (PubMed ID: 33872049)
1. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
[TBL] [Abstract][Full Text] [Related]
2. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Bretagne M; Lebrun-Vignes B; Pariente A; Shaffer CM; Malouf GG; Dureau P; Potey C; Funck-Brentano C; Roden DM; Moslehi JJ; Salem JE
Arch Cardiovasc Dis; 2020 Jan; 113(1):9-21. PubMed ID: 31685432
[TBL] [Abstract][Full Text] [Related]
3. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
5. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
6. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
7. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
8. Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study.
Briggs LG; Reese S; Herzog P; Nguyen DD; Labban M; Alkhatib K; Trinh QD; Morgans AK
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):331-337. PubMed ID: 35436999
[TBL] [Abstract][Full Text] [Related]
9. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System.
Wu B; Shen P; Yin X; Yu L; Wu F; Chen C; Li J; Xu T
Br J Clin Pharmacol; 2023 Feb; 89(2):440-448. PubMed ID: 35349180
[TBL] [Abstract][Full Text] [Related]
10. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
11. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
13. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
14. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
[TBL] [Abstract][Full Text] [Related]
18. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
20. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
